Last reviewed · How we verify

IDEA AG — Portfolio Competitive Intelligence Brief

IDEA AG pipeline: 0 marketed, 0 filed, 2 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
IDEA-033 IDEA-033 phase 3 small molecule target molecular target Cardiovascular
ketoprofen in Diractin® ketoprofen in Diractin® phase 3 NSAID COX-1 and COX-2 Pain management, Inflammation

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 2 shared drug classes
  2. Allergan · 1 shared drug class
  3. AstraZeneca · 1 shared drug class
  4. Amneal Pharmaceuticals, LLC · 1 shared drug class
  5. Antibe Therapeutics Inc. · 1 shared drug class
  6. Apsen Farmaceutica S.A. · 1 shared drug class
  7. American University of Beirut Medical Center · 1 shared drug class
  8. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for IDEA AG:

Cite this brief

Drug Landscape (2026). IDEA AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/idea-ag. Accessed 2026-05-14.

Related